Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zedenoleucel - Marker Cell Therapy

Next Previous
Drug Profile

Zedenoleucel - Marker Cell Therapy

Alternative Names: Autologous cytotoxic T-cell therapeutic - Marker Cell Therapeutics; MT-401; MT-401-OTS; MultiTAA T cells Stage; MultiTAA T-cell therapy; MultiTAA-specific T cells; TAA-specific CTLs; Zelenoleucel

Latest Information Update: 31 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Marker Therapeutics
  • Developer Baylor College of Medicine; Marker Cell Therapy
  • Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Breast cancer
  • Phase I/II Multiple myeloma; Precursor cell lymphoblastic leukaemia-lymphoma; Sarcoma
  • Phase I Myelodysplastic syndromes
  • Discontinued Lymphoma; Ovarian cancer

Most Recent Events

  • 16 Jun 2025 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater, In the elderly) in USA (IV) (NCT06552416)
  • 16 Jun 2025 Phase-I clinical trials in Myelodysplastic syndromes (Second-line therapy or greater, In the elderly) in USA (IV) (NCT06552416)
  • 31 Mar 2025 Marker Therapeutics plans a clinical trial in Acute myeloid leukaemia and Myelodysplastic syndrome in the second half of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top